IL256615B - An il-6 antagonist for use in a method of treating hepcidin-mediated anemia of chronic inflammation in a patient and a method for determining whether the il-6 antagonist will be ineffective in a patient with said inflammation - Google Patents

An il-6 antagonist for use in a method of treating hepcidin-mediated anemia of chronic inflammation in a patient and a method for determining whether the il-6 antagonist will be ineffective in a patient with said inflammation

Info

Publication number
IL256615B
IL256615B IL256615A IL25661517A IL256615B IL 256615 B IL256615 B IL 256615B IL 256615 A IL256615 A IL 256615A IL 25661517 A IL25661517 A IL 25661517A IL 256615 B IL256615 B IL 256615B
Authority
IL
Israel
Prior art keywords
antagonist
inflammation
psidine
ineffective
patients
Prior art date
Application number
IL256615A
Other languages
English (en)
Hebrew (he)
Other versions
IL256615A (en
Original Assignee
Medimmune Ltd
Astrazeneca Pharmaceuticals Lp
Astrazeneca Uk Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57886392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL256615(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd, Astrazeneca Pharmaceuticals Lp, Astrazeneca Uk Ltd, Astrazeneca Ab filed Critical Medimmune Ltd
Publication of IL256615A publication Critical patent/IL256615A/en
Publication of IL256615B publication Critical patent/IL256615B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
IL256615A 2015-07-31 2017-12-27 An il-6 antagonist for use in a method of treating hepcidin-mediated anemia of chronic inflammation in a patient and a method for determining whether the il-6 antagonist will be ineffective in a patient with said inflammation IL256615B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199434P 2015-07-31 2015-07-31
US201562268788P 2015-12-17 2015-12-17
PCT/US2016/044528 WO2017023699A1 (en) 2015-07-31 2016-07-28 Methods for treating hepcidin-mediated disorders

Publications (2)

Publication Number Publication Date
IL256615A IL256615A (en) 2018-02-28
IL256615B true IL256615B (en) 2021-04-29

Family

ID=57886392

Family Applications (2)

Application Number Title Priority Date Filing Date
IL256615A IL256615B (en) 2015-07-31 2017-12-27 An il-6 antagonist for use in a method of treating hepcidin-mediated anemia of chronic inflammation in a patient and a method for determining whether the il-6 antagonist will be ineffective in a patient with said inflammation
IL279308A IL279308A (en) 2015-07-31 2020-12-09 Methods for the treatment of heptidine-mediated disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL279308A IL279308A (en) 2015-07-31 2020-12-09 Methods for the treatment of heptidine-mediated disorders

Country Status (17)

Country Link
US (3) US20170029499A1 (https=)
EP (2) EP3888752A1 (https=)
JP (4) JP2018529756A (https=)
KR (2) KR102889430B1 (https=)
CN (3) CN108026582A (https=)
AU (2) AU2016302768B2 (https=)
BR (1) BR112018001853A2 (https=)
CA (2) CA2991637C (https=)
EA (1) EA201890185A1 (https=)
ES (1) ES2877708T3 (https=)
IL (2) IL256615B (https=)
MX (1) MX2018000778A (https=)
NZ (1) NZ739392A (https=)
SG (1) SG10201913062SA (https=)
TW (3) TW202043482A (https=)
WO (1) WO2017023699A1 (https=)
ZA (1) ZA202003889B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991637C (en) * 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
EP3735421A4 (en) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
CN111217819B (zh) * 2018-11-27 2021-05-14 杭州科巢生物科技有限公司 乌帕替尼的合成方法
JP7701273B2 (ja) 2019-05-01 2025-07-01 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
CN114375205A (zh) * 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20220107252A (ko) 2019-11-29 2022-08-02 키맵 리미티드 생리학적 철분 과다에 대한 치료
CN115243762A (zh) * 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
EP4142721A1 (en) * 2020-04-29 2023-03-08 Bioage Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
AR122933A1 (es) 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
TWI907583B (zh) * 2020-12-11 2025-12-11 大陸商江蘇恒瑞醫藥股份有限公司 Jak抑制劑在腎臟疾病中的應用
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN113502325B (zh) * 2021-07-02 2024-09-10 厦门市妇幼保健院(厦门市优生优育服务中心、厦门大学附属妇女儿童医院、厦门市林巧稚妇女儿童医院) 用于孕期铁营养缺乏风险评估检测试剂盒与应用方法
JP2024540480A (ja) 2021-11-17 2024-10-31 ディスク・メディシン・インコーポレイテッド 腎臓疾患の貧血を処置する方法
AU2023283829A1 (en) * 2022-06-09 2024-11-07 Disc Medicine, Inc. Methods for treating blood loss conditions
EP4615867A1 (en) * 2022-11-11 2025-09-17 Tourmaline Bio, Inc. Methods for the treatment of cardiovascular disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6808194A (en) 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
JP4960096B2 (ja) * 2003-09-22 2012-06-27 ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−６の生物学的効果を減じる化合物の使用
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
JP2008529968A (ja) * 2005-02-08 2008-08-07 国立循環器病センター総長 インスリン様成長因子−１（ｉｇｆ−１）を使用する慢性重症心不全を処置するための新規方法
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
US7820790B2 (en) * 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
AR058135A1 (es) * 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
KR20110112307A (ko) * 2008-11-25 2011-10-12 앨더 바이오파마슈티컬즈, 인코포레이티드 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ­６의 길항제
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
KR101913109B1 (ko) * 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
CN102740888B (zh) * 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
FR2978964B1 (fr) * 2011-08-09 2015-02-20 Conservatoire Nat Arts Composition vaccinale anti-il-6
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
CN104768578A (zh) * 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
CN104903349B (zh) 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US20160130340A1 (en) 2013-10-07 2016-05-12 Alderbio Holdings Llc Dosing regimens using anti-il-6 antibodies for the treatment of rheumatoid and psoriatic arthritis
US9139648B1 (en) * 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CA2991637C (en) * 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료

Also Published As

Publication number Publication date
CA3119498A1 (en) 2017-02-09
AU2019268074B9 (en) 2022-10-20
IL279308A (en) 2021-01-31
AU2016302768B2 (en) 2019-08-22
NZ739392A (en) 2019-10-25
CN121243390A (zh) 2026-01-02
SG10201913062SA (en) 2020-03-30
US20250129151A1 (en) 2025-04-24
CN113117074B (zh) 2025-09-12
CA2991637A1 (en) 2017-02-09
IL256615A (en) 2018-02-28
TWI778140B (zh) 2022-09-21
US20210292405A1 (en) 2021-09-23
JP2023169297A (ja) 2023-11-29
AU2016302768A1 (en) 2018-02-15
EP3888752A1 (en) 2021-10-06
TWI653339B (zh) 2019-03-11
ES2877708T3 (es) 2021-11-17
JP2025128207A (ja) 2025-09-02
EP3329018B1 (en) 2021-03-31
US20170029499A1 (en) 2017-02-02
CN108026582A (zh) 2018-05-11
JP2018529756A (ja) 2018-10-11
AU2019268074B2 (en) 2022-06-02
JP7691464B2 (ja) 2025-06-11
TW201928063A (zh) 2019-07-16
JP2022033925A (ja) 2022-03-02
EP3329018A1 (en) 2018-06-06
EA201890185A1 (ru) 2018-07-31
TW202043482A (zh) 2020-12-01
KR20180058708A (ko) 2018-06-01
KR102889430B1 (ko) 2025-11-21
HK1249923A1 (en) 2018-11-16
JP7386838B2 (ja) 2023-11-27
WO2017023699A1 (en) 2017-02-09
KR102709681B1 (ko) 2024-09-26
BR112018001853A2 (pt) 2018-09-25
CA2991637C (en) 2022-07-05
TW201718873A (zh) 2017-06-01
KR20240144460A (ko) 2024-10-02
CN113117074A (zh) 2021-07-16
ZA202003889B (en) 2023-03-29
AU2019268074A1 (en) 2019-12-12
NZ757487A (en) 2025-03-28
MX2018000778A (es) 2018-08-15
EP3329018A4 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
IL256615B (en) An il-6 antagonist for use in a method of treating hepcidin-mediated anemia of chronic inflammation in a patient and a method for determining whether the il-6 antagonist will be ineffective in a patient with said inflammation
CY2024016I2 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας
IL283429A (en) Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
IL261805A (en) Method and apparatus for delivery of therapeutic agents
IL245219B (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
SI3661954T1 (sl) Muteini interlevkina-21 in postopki zdravljenja
IL288340A (en) Seladelpar and salts thereof for use in treating cholestatic pruritus
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
IL244607A0 (en) Apparatus and method for determining physiologic perturbations of a patient
SI3368069T1 (sl) Uporaba zaviralcev miostatina in kombinirane terapije
EP2991600A4 (en) MICRO-CLOSURES AND RELATED METHODS OF SKIN TREATMENT
PL3325509T3 (pl) Przeciwciała anty-TfR oraz ich zastosowanie w leczeniu zaburzeń proliferacyjnych i zapalnych
IL258768A (en) Glycan-interacting compounds and methods of use
IL241222A0 (en) Devices and methods for multi-focus ultrasound therapy
SI3436048T1 (sl) Neoantigeni in načini uporabe
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
IL241026B (en) Headset for treatment and assessment of medical conditions
DK3043763T3 (da) Stimulerings- og behandlingsindretning
IL239922A0 (en) Solid solution compositions and use in chronic inflammation
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
PL3806898T3 (pl) Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
PL3117777T3 (pl) Metoda tomografii rozpraszającej i urządzenie do tomografii rozpraszającej
PT3319612T (pt) Oxisteróis e métodos de utilização dos mesmos
PT3027603T (pt) Inibidores de rorc2 de heterobicicloarilo e métodos de utilização dos mesmos

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed